Last reviewed · How we verify
Extra-fine hydrofluoroalkane beclomethasone MDI
Glucocorticoid receptor agonist
Glucocorticoid receptor agonist Used for Asthma, Chronic obstructive pulmonary disease (COPD).
At a glance
| Generic name | Extra-fine hydrofluoroalkane beclomethasone MDI |
|---|---|
| Also known as | Qvar® |
| Sponsor | Research in Real-Life Ltd |
| Drug class | Glucocorticoid |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | Phase 2 |
Mechanism of action
Beclomethasone acts as a potent glucocorticoid receptor agonist, which leads to anti-inflammatory and immunosuppressive effects.
Approved indications
- Asthma
- Chronic obstructive pulmonary disease (COPD)
Common side effects
- Oral thrush
- Headache
- Nausea
- Vomiting
- Cough
- Dysphonia
- Hoarseness
- Pneumonia
- Sinusitis
- Upper respiratory tract infection
Key clinical trials
- Real-world Effectiveness and Cost-effectiveness of Leading Inhaled Corticosteroids in Asthma Management
- Qvar Therapy in Smoking Asthmatics
- Qvar Versus Clenil, a General Practice Research Database Study
- Real-life Effectiveness and Cost-effectiveness of Qvar Versus FP and BDP in the Management of COPD
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: